Market closedNon-fractional
Cartesian Therapeutics/RNAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Ticker
RNAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Gaithersburg, United States
Employees
38
RNAC Metrics
BasicAdvanced
$302M
Market cap
-
P/E ratio
-$55.78
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$302M
Financial strength
Current ratio
3.031
Quick ratio
2.941
Long term debt to equity
-7.045
Total debt to equity
-8.953
Interest coverage (TTM)
-34.12%
Management effectiveness
Valuation
Price to revenue (TTM)
3.436
Price to book
-0.79
Price to tangible book (TTM)
-0.29
Price to free cash flow (TTM)
-1.509
Growth
What the Analysts think about RNAC
Analyst Ratings
Majority rating from 5 analysts.
RNAC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.8M
-29.27%
Net income
-$57M
-68.02%
Profit margin
-979.31%
-54.78%
RNAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.10
-$1.80
-$41.70
-$10.50
-
Expected
-$2.40
-$1.75
-$1.05
-$0.89
-$1.32
Surprise
-12.50%
2.86%
3,871.43%
1,086.44%
-
RNAC News
AllArticlesVideos
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
GlobeNewsWire·3 days ago
Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs
Investors Business Daily·4 days ago
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Reuters·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $302M as of July 06, 2024.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of July 06, 2024.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.
Buy or sell Cartesian Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.